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Background: Previous studies demonstrate changes of autoantibody concentrations against retinal and optic nerve
head antigens in the serum of glaucoma patients in comparison to healthy persons. These antibodies belong to the
natural autoimmunity. Previous studies showed up regulated, but also significantly down-regulated autoantibody levels.
These antibodies have the ability to influence protein profiles of neuroretinal cells and possibly hold neuroprotective
potential, as we have been able to demonstrate before. Aim of this study was to analyse the serum and antibody effect
of glaucoma patients on neuroretinal cells in more detail and also determine the impact of antibodies found down-
regulated in glaucoma patients on the pathogenesis of the neurodegenerative disease glaucoma.
Methods: Neuroretinal cells (RGC-5) were incubated with serum either from glaucoma patients or healthy controls for
24 h. Mass spectrometric analysis was performed after cell lysis. Furthermore the neuroretinal cells were preincubated
with different and concentrations of 14-3-3 antibodies (0.005, 0.1, 0.5, 1, 5 and 10 μg/ml) and then stressed with H2O2,
staurosporine or glutamate. Viability tests were performed with crystal violet and ROS tests with DCFH-DA. Antibody
location in the cell after antibody incubation was performed with immunoccytochemical methods. Additionally mass
spectrometric analysis was performed with the cells after antibody incubation.
Results: Protein expression analysis with Maldi-Orbitrap MS showed changes in the expression level of regulatory
proteins in cells incubated with glaucoma serum, e.g. an up-regulation of 14-3-3 and a down-regulation of Calmodulin.
After preincubation of the cells with anti-14-3-3 antibody and stressing the cells, we detected an increase in viability of
up to 22 % and a decrease in reactive oxygen species (ROS) of up to 31 %. Proteomic 1 analysis involvement of the
mitochondrial apoptosis pathway in this protective effect and immunohistochemical analysis showed an antibody
uptake in the cells.
Conclusion: We found significant effects of serum antibodies on proteins of neuroretinal cells especially of the
mitochondrial apoptosis pathway. Furthermore we detected a protective potential of antibodies down-regulated in
glaucoma patients. The changed autoantibodies belong to the natural autoimmunity. We conclude that changes in
the natural autoimmunity of patients with glaucoma can negatively impact regulatory functions.
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The pathogenesis of neurodegenerative diseases is often
poorly understood. Neurodegenerative diseases are char-
acterised by progressive nervous system dysfunction and
an accompanying atrophy of the affected central or per-
ipheral nervous system [1]. As in other neurodegenerative
diseases, such as amyotrophic lateral sclerosis, Alzheimer’s
or Parkinson disease, glaucoma leads to the apoptotic loss
of one specific neuron population, the retinal ganglion
cells (rgc) [2]. An atrophy of central structures such as the
lateral geniculate nucleus [3] can also be found. With an
estimated prevalence of at least 60 million cases world-
wide [4], glaucoma can be counted to the list of the most
common neurodegenerative diseases [5].
This heterogeneous group of eye diseases, with a still
unknown pathogenesis, demonstrates with a progressive
loss of retinal ganglion cells (rgc), optic nerve degener-
ation and visual fields loss, finally leading to blindness
[6]. 2.65 % of the world’s population above the age of 40
suffers from glaucoma [7]. The major risk factor for de-
veloping glaucoma found in approximately 70 % of the
patients is an increased intraocular pressure (IOP) [8, 9].
Other pathogenesis factors leading to apoptosis of rgc
[10, 11] such as elevated levels of reactive oxygen species
(ROS) [12, 13] or elevated glutamate levels are discussed
[14, 15]. Furthermore, there is strong evidence that an
immunologic component is involved in glaucoma patho-
genesis. Altered autoantibody levels in the serum of
glaucoma patients e.g. against heat shock protein (hsp)
60 [16], alpha crystallin and hsp27, gamma enolase [17]
and glycosaminoglycans as well as against human retinal
antigens, such as against cellular retinaldehyde-binding
protein and retinal-S-antigen [18, 19] have been demon-
strated. Interestingly, the studies were not only able to
detect higher concentrations of different autoantibodies
in glaucoma patients, but also lower concentrations of
many autoantibodies in comparison to healthy people
[20]. Many of the serum immunoglobulins in healthy
people belong to the so called natural autoimmunity [21,
22]. These autoantibodies do not cause diseases and in
contrast are considered as regulatory factors [23]. In
general it is known that up-regulated autoantibodies can
be auto-aggressive and lead to pathogenic conditions,
such as the antibody against postsynaptic nicotinic
acetylcholine receptor in patients suffering from myas-
thenia gravis [24]. The role of the down-regulated auto-
antibodies found e.g. in glaucoma patients, but also in
patients suffering from other neurodegenerative diseases,
such as Alzheimer’s disease [25], so far is not known.
We assume that the down-regulation of some of the
antibodies can lead to changes in the regulatory function
of these antibodies and therefore could be involved in
the pathogenesis of the neurodegenerative disease
glaucoma.The aim of this study was to investigate the induced
effect of glaucomatous serum and an antibody found
down-regulated in glaucoma patients on viability, react-
ive oxygen levels (ROS) as well as the proteomics of
neuroretinal cells. In previous studies we were able to
demonstrate that the antibodies of glaucoma patients in
general have a large influence (59 %) on the protein pro-
files of neuroretinal cells [26]. Therefore we analysed the
changes of proteins and their pathways in more detail.
Additionally we enlighten whether down-regulated anti-
bodies could have an impact on the disease glaucoma.
In summary we demonstrate that serum of glaucoma
patients can change intracellular concentrations of im-
portant regulatory proteins such as the protein kinase
inhibitor 14-3-3, which has a major regulatory function
on the MAPK/ERK pathway, or Calmodulin. Further-
more we were able to show that the antibody against
14-3-3, which is down-regulated in glaucoma patients
(p < 0.01) (see Additional file 1: Figure S1), has protect-
ive effects on stressed neuroretinal cells, documented




The used reagents were purchased from Sigma Aldrich,
St. Louis, MO, US if not stated otherwise. L-alanyl-L-
glutamine was purchased from Biochrom AG (Berlin,
Germany). The rabbit anti-14-3-3 abs for cell incubation
and the secondary antibody goat-anti-rabbit IgG-H&L
(FITC) were purchased from Abcam (Cambridge, UK),
H2O2 and paraformaldehyde from Carl Roth GmbH
(Karlsruhe, Germany), Staurosporine from Calbiochem
(San Diego, CA), 70 % ethanol, formic acid, trifluoroace-
tic acid (TFA) and acetonitrile (ACN) from Merck
(Darmstadt, Germany), 14-3-3 antibodys for immunohis-
tochemical staining from Lifespan (Seattle, WA), the
BCA Pierce Protein Assay kit from Fisher scientific
(Waltham, MA), Trypsin from Promega (Mannheim,
Germany), wheat germ agglutinin conjugate with tetra-
methylrhodamin (WGA) from Invitrogen (Karlsruhe,
Germany), vectashield mounting medium with 4’,6-dia-
midino-2-phenylindole (DAPI) from Vector Laboratories
(California, USA) and HPLC H2O from Applichem
(Darmstadt, Germany).
Serum samples
The serum was collected from patients suffering from
POAG according to the classification of the guidelines of
the European glaucoma society as well as from healthy
volunteers after given written informed consent. Further-
more, patients suffering from autoimmune diseases or
other neurodegenerative diseases were excluded from the
study. The studies were performed in accordance with the
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man subjects. The samples were age matched. Ethics
approval: No: 837.219.07 (5754); Ethics committee of the
Landesärztekammer Rhineland-Palatinate.
Cell culture
RGC-5 cells, a neuroretinal cell line of mouse origin,
provided by Dr. Neeraj Agarwal, were used as model for
retinal cells of neuronal origin [27]. They were grown in
75 culture flasks in Dulbecco’s modified eagle medium
supplemented with 10 % fetal calf serum (FCS), 100 U/
ml penicillin, 100 U/ml streptomycin and 4 % L-alanyl-
L-glutamine. The cells were cultivated in a humidified
incubator at 37 °C with 95 % air and 5 % CO2 and were
passaged when they reached a confluence of 80 %.
Cell treatment with different serum types
250 000 RGC-5 cells were transferred to culture dishes
with an 82.7 mm inner diameter. After 24 h the cells
were incubated with medium containing 5 % FCS and
either 5 % serum from healthy people or 5 % serum
from POAG patients (n in each experimental group: 8).
Each individual serum was used for an individual run.
The cells were incubated with the different serum types
for 24 h. After 24 h the medium was discarded and the
cells were washed twice with phosphate buffered saline
(PBS). Cell lysis was performed and the detached cells
were transferred to an Eppendorf tube with lysis buffer
[Urea 9.5 M, Chaps 2 %, DTT 1 % + proteinase inhibitor
mix (P 1860)]. Furthermore an ultrasonic pulse echo in-
strument [Labsonic®M (Sartorius)] was used to perform
additional cell lysis. Protein concentration of the samples
was determined with the method of Lowry [28]. After
the protein concentration was determined, a sample-
pool for each experimental group was created with a
total amount of 80 μg protein. The pooled samples were
separated with a 1D SDS gel. Each lane was divided into
15 pieces and digested with trypsin in order to measure
the peptide profile with Maldi- Orbitrap MSMS.
Protein profiling with Maldi- Orbitrap MSMS
The protein profiles were analysed with Maldi- LTQ
Orbitrap XL using Maldi-steel targets. The samples were
dried in a concentrator and acidified with 0.1 % TFA. C-
18 ZipTips (Millipore, Billerica, MA) were used to purify
the samples and the peptides were eluted directly onto a
Maldi Target with 40 % ACN and 60 % ACN. Measure-
ments were performed according to the manufacturers’
protocol.
Protein profiling with capillary LC-ESI-MSMS
The protein profiles were analysed with capillary LC-
ESI-MSMS using a C-18 pre-column (30 mm x 0.5 mm)
and a C18 analytical column (150 mm x 0.5 mm, bothThermo Scientific,). A Rheos Allegro HPLC Pump
(Thermo Scientific) was the solvent delivery system. The
pump flow rate was 200 μl/min, and reduced to a col-
umn flow of 10 μl/min (M-472 graduated microsplit
valve (Upchurch, Scientific, USA). With two running
buffers (A (98 % H2O, 1.94 % ACN, 0.06 % methanol,
0.05 % TFA) + B (95 % ACN, 3 % methanol, 2 % H2O,
0.05 % TFA) a linear gradient of 80 min was performed
(0–47 min: 0–100 % B, 47–49 min: 100 % B, 49–58:
100 %–0 % B, 58–80 min: 0 % B). Mass spectra were ob-
tained using an LTQ OrbitrapXL.
Cell treatment with 14-3-3 antibodies and different stress
factors
RGC-5 cells were seeded in 24 well plates. Depending
on the stress factor and therefore the overall incubation
time, the cells were either seeded with 45000 cells per
well (for the experiments with H2O2 and staurosporine)
or 40000 cells per well (experiments with the stress fac-
tor glutamate). The cells were preincubated with differ-
ent concentrations of chicken polyclonal anti 14-3-3
sigma antibodies (0.005, 0.1, 0.5, 1, 5 and 10 μg/ml) for
3 h. As an additional control group the cells were incu-
bated with a non-retina specific antibody against myo-
globin. To induce apoptosis the cells were stressed with
staurosporine (1.5 μM for 5 h) or glutamate (20 mM for
24 h). Furthermore oxidative stress was induced by incu-
bating the cells with 50 μM H2O2 for 1 h (n in each ex-
perimental group = 4). We used this amount of H2O2
because test showed that we were able to detect a rise in
ROS without a loss of viability of the cells using this
concentration. Subsequently cell viability tests and ROS
measurements were performed. Figure 1 shows an over-
view of the experimental setup.
Cell viability test
Cell viability was assessed with crystal violet staining. The
cells were fixed with 3 % paraformaldehyde (15 min) and
rinsed with PBS. Subsequently the cells were stained with
0.1 % crystal violet solution for 20 min. Excess stain was
removed by washing the plates with distilled water three
times. The bound stain of the viable cells was resolved in
70 % ethanol for 3 h. The supernatants were read with the
Multiscan ascent plate reader (Thermo scientific) at
570 nm. The absorption was expressed as a percentage of
the control cells, which were only treated with the stress
factor. An unpaired student t-test was used to compare
the data obtained and was realized with Statistica (Statsoft,
Tulsa, Oklahoma, USA). A p value < 0.05 was significant
and a p value < 0.01 was declared highly significant.
ROS-test
To quantify ROS we used 2’,7’-dichlorodihydrofluores-
cein-diacetate (DCFH-DA). Intracellular esterases’ and
Fig. 1 Experimental setup for RGC-5 cells incubated with 14-3-3 ab. The cells were seeded in 24 well plates and were let to rest for 24 h. Then
antibody preincubation of the cells with different antibody concentrations was performed for 3 h. The control cells not incubated with the antibody
were incubated with normal medium for the same amount of time. After 3 h the medium containing the antibodies or the control medium was
replaced with medium containing one of the stress factors (glutamate, staurosporine or H2O2). Depending on the stress factor, the incubation time
varied. After stressing the cells, viability tests with crystal violet staining was performed with all cells, and ROS level measurements were performed in
the cells stressed with H2O2
Bell et al. BMC Ophthalmology  (2015) 15:64 Page 4 of 13ROS convert the non-fluorescence stain 2’, 7’ dichlorodi-
hydrofluorescein (DCFH) to the fluorescent stain
dichlorofluorescein (DCF). Cells were loaded with
10 mM DCFH-DA in the incubation chamber for
15 min. Then the culture medium was replaced, to re-
move the unbound DCFH-DA. To generate ROS, 50 μM
H2O2 was added. The fluorescence was measured by
using the microplate reader fluoroscan ascent (Thermo
scientific) with excitation/emission wavelengths of 485/
538 nm. The absorption was expressed as a percentage
of the control cells, which were only treated with 50 μM
H2O2. The ROS- level was normalised by measuring the
viability of the cells in the same well. An unpaired stu-
dent t-test was used to compare the data obtained and
was realized with Statistica.
Immunocytochemical staining
RGC-5 cells were grown in μ-slide IV (Ibidi GmbH,
Munich, Germany) and subsequently washed with PBS.
Then the cells were fixed with 3 % paraformaldehyde for
15 min and incubated with 0.25 % Triton-X-100 for
12 min. After 3 wash steps with PBS, the cells were
treated with 1 % bovine serum albumin for 20 min.
Afterwards, the cells were incubated with 2 μg/ml rabbit
polyclonal anti 14-3-3 sigma antibodies overnight, thengently washed 3 times with PBS and incubated with
Goat polyclonal secondary antibody to rabbit IgG-H&L
conjugated with FITC for 1.5 h. After 3 washing steps
with PBS the cells were visualized with a fluorescence
microscope (Leica Microsystem, Heidelberg, Germany).
To investigate the antibody uptake in living cells, the
cells were preincubated with 10 μg/ml rabbit polyclonal
anti 14-3-3 sigma abs for 3 h and then washed with PBS
to remove unbound antibodies. Controls were preincu-
bated with medium not containing the polyclonal anti
14-3-3 sigma abs. The cells then were treated as de-
scribed above and visualized with a Leica fluorescence
microscope and using Lucia G/F software.
Cell lysate preparation
For proteomic analysis the cells incubated with anti-14-3-
3 antibody were grown in 60 x 15 mm cell culture dishes
and incubated with 0.5 μg/ml chicken polyclonal anti 14-
3-3 sigma antibodies. Cells were detached using cell dis-
sociation solution (CDS) and lysed by freezing at −80 °C
after adding 0.1 % Dodecyl-D-β- Maltosid with proteinase
inhibitor. Additionally, the cells were treated with a sonic-
ation bath for 1 min. After centrifugation, the supernatant
was used for determining the protein concentration by
BCA Pierce Protein Assay kit.
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Protein separation was performed with a denaturing gel
electrophoresis. Each lane was cut into 17 pieces, incu-
bated with acetonitrile (ACN) and ammonium bicarbon-
ate (AB) and dried in a concentrator. The pieces were
digested with trypsin (0.7 μg Trypsin in 80 % HPLC
H2O, 10 % ACN, 10 % AB) over night. The supernatant
was collected and the remaining proteins were dissolved
with an extraction buffer (38 % HPLC H2O, 2 % formic
acid, 60 % ACN) for 30 min. The supernatants then
were pooled, dried in a concentrator and acidified with
0.1 % trifluoroacetic acid. C-18 ZipTips were used to
purify the samples. The samples were measured with ca-
pillary LC-ESI-MSMS as described above.
Data processing
The obtained mass spectra measured with Maldi- Orbi-
trap MSMS were used for an identification and quantifi-
cation of the proteins. Using Mascot search engine, the
spectra were transferred to SwissProt database. The
identification of the proteins was performed using Mus
musculus as taxonomy and trypsin as digesting enzyme.
This information is necessary for database to calculate
the theoretical mass. Furthermore one missed cleavage
was allowed. As MALDI was used, the charge state was
set to 1+. The error window of the mass was set at
100 ppm and 0.8 Da. The normalisation and quantifica-
tion of the peptides was performed with PSP (former
P2M), our in-house proteomics pipeline software and
transferred to Statistica software for quantification, as
described before [29].
The obtained mass spectra measured with LC-ESI-
MSMS were used for identification and quantification
with Maxquant (Max Planck Institute of Biochemistry,
Martinsried, Germany). The tolerance in mass precision
for MS/MS was 20 ppm and 0.5 Da. The protein and
peptide false discovery rate were set to 0.01 and the
minimum peptide length was 6 amino acids. The evalu-
ation was implemented with Ingenuity Pathway Analysis
(IPA) Software. Only proteins with a 2-fold changed ex-
pression upon 14-3-3 sigma antibody treatment were in-
cluded in the analysis. The statistical significance of each
pathways was calculated by IPA using a Fisher Exact test
p < 0.05.
Results
Changes in protein profiles of cells incubated with POAG
serum
We were able to detect complex protein profiles of
RGC-5 cells incubated either with primary open angle
glaucoma (POAG) or healthy serum. The measurements
of the pooled samples (one of each group, consisting of
a mixture of eight samples) with Maldi-Orbitrap MSMS
showed 182 identified proteins of which 39 weresignificantly differently regulated (< −2 fold down-
regulated or > 2 fold up-regulated) in cells incubated
with POAG serum in comparison to healthy serum. Sig-
nificant changes could be found throughout the cell, e.g.
cytosolic proteins, as well as mitochondrial or nucleolus
proteins. The most significantly up-regulated protein
was identified as 14-3-3, a regulatory protein in
eukaryotic cells. 14-3-3 protein was up-regulated 18 fold
in cells incubated with POAG serum (Fig. 2, 14-3-
3F_MOUSE). In comparison, Calmodulin (Fig. 2, CALM),
a binding partner of 14-3-3 [30], was shown to be down-
regulated nearly 6 fold (−5.6). Proteins, known from other
glaucoma studies, such as zink-finger protein (CNPB),
were detected to also be differently regulated in this study
(Fig. 2).
Protective effect of 14-3-3 antibodies
The effect of 14-3-3 antibodies (ab) on the cells was de-
termined with crystal violet and DCFH-DA.
An increased cell viability of 22 % (p < 0.01) was mea-
sured after preincubation of the cells with 10 μg/ml 14-3-
3 ab and additional stress with H2O2 (Fig. 3), as well as a
significantly decreased ROS-production of 31 % (p < 0.01)
(Fig. 3). We could indicate a significantly increased viabil-
ity of 12 % (p < 0.01) when incubating the cells with
0.5 μg/ml 14-3-3 ab and of 7 % (p < 0.05) when incubating
the cells with 1 μg/ml 14-3-3 ab and stressing with staur-
osporine (Fig. 4a).
The cells treated with glutamate showed a decreased
viability of 51 %. We detected that cells incubated with
0.5, 1 and 5 μg/ml 14-3-3 antibodies showed an in-
creased viability of up to 12 % (p < 0.01) in comparison
to the control cells stressed with glutamate (Fig. 4b). In
contrast, no positive or negative effect of the anti-
myoglobin antibody, which served as a control, on the
viability of the cells could be detected (see Additional
file 2: Figure S2). Furthermore we could not detect any
effect of the 14-3-3 antibody on non-stressed RGC-5
cells (see Additional file 3: Figure S3).
Expression of 14-3-3 and 14-3-3 antibody binding
To determine, whether RGC-5 cells express 14-3-3 and
were the antibody binds in living cells we performed an
indirect immunofluorescence staining. In permeabilised
RGC-5 cells we could show binding of the 14-3-3 anti-
body in the cytoplasm (see Fig. 5). We further investi-
gated the uptake of 14-3-3 antibodies in living RGC-5
cells. We were able to show the uptake of 14-3-3 anti-
bodies in vesicles after preincubation of living RGC-5
for 3 h (Fig. 6).
Proteomic analysis
To further investigate the effect of 14-3-3 abs on the
protein expression of RGC-5, proteomic analyses were
Fig. 3 Protective effects of 14-3-3 antibody on RGC-5 stressed with
H2O2. RGC-5 cells were preincubated with different concentration of
14-3-3 antibodies for 3 h and additionally stressed with 50 μM H2O2
for 1 h. This amount of H2O2 was used, as we did not want to pro-
duce a loss of viability through H2O2 our aim was to just increase
ROS in the cells. The graph shows the ROS levels in % in the cells
(blue line) as well as the viability (red line) of the cells after pre-
incubation with different 14-3-3 antibody concentrations and stress
with 50 μM H2O2 for 1 h. N in each experimental group is 4. Signifi-
cantly decreased ROS levels (−31 %) were measured in the cells in-
cubated with 10 μg/ml 14-3-3 antibodies. ROS-production was
measured using DCFH-DA and expressed as percent of the control
cells, which were only treated with H2O2. Significantly increased via-
bility (+22 %) was measured for the cells incubated with 10 μg/ml
14-3-3 antibodies. Viability was measured using crystal violet and
expressed as percent of the control cells additionally incubated with
H2O2 (* = p < 0.05; **p < 0.01)
Fig. 2 Changes of proteins in RGC-5 cells incubated with POAG serum versus healthy serum. Proteomic measurements of the pooled samples of
the cells incubated with POAG serum or healthy serum were performed. Each pooled sample contained protein from each of the 8 samples of
either the POAG or the healthy group. After identification of the proteins a quantification of the proteins of the cells incubated with POAG serum
in comparison to healthy serum was performed. The graph shows the changes in %. The most up-regulated protein in the cells incubated with
POAG serum was 14-3-3 eta. But also proteins such as Calmodulin (CALM) or zink-finger protein (CNBP) were significantly differently regulated.
Proteins up- or down-regulated more than 2 fold (100 %) were considered to be statistically significant
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1204 proteins of which 225 were significantly differently
regulated in cells incubated with 14-3-3 abs (>2 fold in-
creased or < 2 fold decreased) (see Additional file 4:
Table S1). The pathway analysis (performed with IPA)
showed that many of the differently regulated proteins
belong to apoptosis signalling pathways of the cells. We
could indicate several changed proteins, such as BAX,
BIRC6, PRFA2, S100A4, VDAC 1/2/3 and ERK1, which
are involved in the regulation of the mitochondrial apop-
tosis pathways. BAX, PRFA1, VDAC 1/2/3 and S100A4
were significant down-regulated and BIRC6 and ERK1
were significant up-regulated in cells treated with 14-3-3
abs in comparison to untreated cells (Fig. 7a).
Discussion
14-3-3 proteins, a group of proteins with many binding
partners, play an important role in a wide range of cellu-
lar processes and are well known to be altered in many
neurodegenerative diseases [31]. In general 14-3-3, a
protein kinase inhibitor, has adjudicated anti- apoptotic
features. Studies have been able to show the regulator
function of 14-3-3 on the MAPK/ERK pathway, protect-
ing cells from apoptosis [32]. The MAPK/ERK pathway
can be activated by several extracellular signals and
stressors, such as oxidative stress [33], as well as intra-
cellular signals and pathways [34]. In an inactive state
14-3-3 is bound to Raf-1. Briefly, after binding activated
Ras and dephosphorylation of S259, 14-3-3 is released
from Raf-1 [35]. This evokes activation of the MAPK/
ERK pathway with resulting changes of the gene tran-
scription and protein expression, resulting in different
cell reactions such as proliferation, but also apoptosis
Fig. 4 Viability of glutamate and staurosporine stressed RGC-5 upon 14-3-3 sigma antibody treatment. RGC-5 were preincubated with different 14-3-3
antibody concentrations and additionally stressed with 20 mM glutamate for 24 h, or 1.5 μM stauorsporine for 5 h. Cell viability was determined using
crystal violet and expressed as percent of the control cells + the stress factor (glutamate or staurosporine) (* = p< 0.05; **p< 0.01). N in each experimental
group is 4. a: Increased highly significant and significant cell viability of up to 7 % was demonstrated after the cells were preincubated with 0.5, 1 μg/ml
14-3-3 sigma antibodies and additionally stressed with staurosporine. b: Increased cell viability in a range of 0.05-5 μg/ml 14-3-3 antibodies were obtained
after the cells were stressed with glutamate, whereby the result of 0.5 μg/ml is highly significant and of 1.5 μg/ml is significant. We were able to detect an
increase of viability of up to 12 %
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study, could be an indicator for the activation of the
MAPK/ERK pathway. This could be interpreted either
that more protective potential is needed in the stressed
cells in order to deactivate Raf-1, or possibly we are de-
tecting 14-3-3 after detachment from Raf-1. Other stud-
ies using an experimental glaucoma model also showed
elevated levels of 14-3-3 protein in the rgc, as well as
other significantly changed proteins also found in this
study, such as the zinc-finger protein [30]. 14-3-3 pro-
teins are known to be involved in many neurodegenera-
tive diseases. 14-3-3 eta was detected as up-regulated in
and around Alzheimer plaques [37], and down-regulated
in Lewy bodies in Parkinson’s disease [38]. Another af-
fected pathway, which is linked to 14-3-3 is involved in
the calcium homeostasis of cells and therefore is also
important for cell survival [39]. Calmodulin, found
down-regulated in cells incubated with glaucoma serum,
interacts with calcium/calmodulin dependant protein
kinase II, which is an N-Methyl-D-aspartate (NMDA)
receptor associated protein. The NMDA receptor is
thought to play a role in the pathogenesis of glaucoma
and in the apoptosis of retinal ganglion cells. A certain
level of calcium/calmodulin dependant protein kinase IIseems to be important to protect rgc from external fac-
tors such as an elevated glutamate level [40] although
there is a controversial discussion about the role of up-
or down-regulation of calcium/calmodulin dependant
protein kinase II when involved in neurodegeneration
[41]. Protein kinase C, which is inhibited by 14-3-3, is
involved in NMDA receptor trafficking in combination
with the activation of the calcium/calmodulin dependant
protein kinase II [42].
Clinical and experimental studies show, that autoanti-
bodies are involved in the changes detected in the cells.
Several clinical trials show altered autoantibody profiles
in the serum of patients suffering from different glau-
coma forms (normal tension glaucoma, primary open
angle glaucoma) or ocular hypertension [43, 44]. We
found that cells react differently depending on the type
of glaucoma serum they were incubated with [26]. We
found that the antibodies in the serum of glaucoma pa-
tients have a large effect of nearly 60 % on the protein
profiles of the cells [26]. Glaucoma is not the only neu-
rodegenerative disease with altered autoantibody levels.
Studies were able to show a significant down regulation
of autoantibodies in the serum of Alzheimer patients in
comparison to healthy controls [25, 45].
Fig. 5 Expression of 14-3-3 sigma in RGC-5 revealed by indirect immunfluorescence. RGC-5 cells were fixed, permeabilised, blocked and incubated
with rabbit polyclonal anti 14-3-3 antibodies. Subsequently the cells were incubated with Goat polyclonal secondary antibody to rabbit IgG-H&L
conjugated with FITC. The cells were visualized with a fluorescence microscope. The pictures show that 14-3-3 was expressed in all cells and it
seems to be distributed in the cytoplasm
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was tested within this study and we found that low con-
centrations of 14-3-3 abs had protective effects on neu-
roretinal cells.
Our proteomic measurements show that these effects
are mediated via the mitochondrial apoptosis pathway.
The proteins BAX, BIRC6. PRFA2, S100A4, VDAC 1/2/3
and ERK1 where regulated in a significantly different
way in cells incubated with the abs and are involved in
the regulation of the intrinsic apoptosis pathway (Fig. 7b).
Pro-apoptotic BAX, a member of the Bcl-2 family, was
down-regulated in cells incubated with 14-3-3 abs. It
plays an important role in the intrinsic apoptotic path-
way by binding mitochondrial VDAC which leads to the
release of cytochrome c and finally to the initiation of
apoptosis [46]. BAX, as well as its transcription factor
p53, are associated with neurodegenerative diseases [47].
Deficiency of BAX in DBA/2 J mice protects rgc from
cell death [48]. It also is increased in a mouse model of
glaucoma [49]. Tumour suppressor p53 is a key regula-
tor of apoptosis and also plays a role in glaucoma [50].
14-3-3 interacts with p53 and positively regulates its
transcriptional activity. It also stabilizes p53 and is in-
volved in the nuclear export and modulation of tumour
suppressing activity [51]. Other proteins also were regu-
lated in an anti-apoptotic manner such as S1004 and
PRAF2 which were down-regulated in this study. They
both can lead to apoptosis [52, 53]. The anti-apoptoticprotein BIRC6 belongs to the inhibitor of apoptosis
(IAP) family and was up-regulated in cells incubated
with 14-3-3 antibodies. BIRC6 is up-regulated in tu-
mours and inhibits active caspase 3 through binding
with its BIR domain [54].
Additionally an increased expression of ERK was
found in 14-3-3 ab incubated cells. Activated ERK1 is
able to phosphorylate many cytoplasmic as well as nu-
clear targets, which leads to cell proliferation and differ-
entiation [55] and participates in mitochondrial
apoptosis [56, 57]. Studies with experimental rat glau-
coma models show that the activation of ERK leads to
increased survival of rgc after ocular hypertension sur-
gery [58]. Staurosporine leads to changes in the phos-
phorylation as well as activation status of ERK [59]. The
increased ERK expression in the cells incubated with 14-
3-3 antibodies could be the link to the protective effect
of the 14-3-3 antibody on staurosporine stressed cells.
Furthermore, increased ERK1 expression could result in
phosphorylation of BAD [60, 61] and provide survival of
stressed RGC-5. This could be the mechanism for the
increased viability and reduced ROS levels of the cells
stressed with H2O2. Cellular H2O2 stress induces ele-
vated ROS expression, which increases the expression of
JNK-mitogen activated protein kinase (MAPK). JNK it-
self leads to caspase activation, which contributes to
apoptosis of cells [62]. JNK activation also leads to phos-
phorylation of 14-3-3 and this consequently promotes
Fig. 6 14-3-3 sigma antibody uptake of RGC-5 revealed by indirect immunfluorescence. Living cells were preincubated with polyclonal rabbit anti
14-3-3 antibodies and then fixed, permeabilised, blocked and stained with Goat polyclonal secondary antibody to rabbit IgG-H&L conjugated with
FITC. a: Bright light microscopy picture. b: Corresponding fluorescence micrograph merged with bright light. Red Arrows indicate vesicles, which
contain 14-3-3 sigma antibodies, showing antibody uptake into the intact cell
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for retinal ganglion cells [30].
This mechanism was most likely triggered by antibody
uptake in vesicles near the nucleus of the cells, as this
was detected in the immunohistochemical staining.
Antibodies are large proteins with a molecular weight of
140–150 kDa. Antibody uptake of Hsp 27 ab has been
demonstrated in retinal ganglion cells [63] and it also
was supposed that the antibody can modulate its anti-
gen, by inhibiting the protective function or even inacti-
vating it. In general the mechanisms by which antibodies
are transferred into cells, bind to their antigen or trans-
locate into the nucleus or other organelles are not
understood very well, one possible mechanism is medi-
ated by myosin 1. Studies show the uptake of anti-DNAantibodies into living cells, mediated by myosin1. The
internalized anti-DNA antibodies interact with DNAse
in the cytoplasm and inhibit their enzymatic activity.
The antibodies were furthermore transferred into the
nucleus and recycling to the cell membrane [64].
Patients with other neurodegenerative diseases also
show changes in natural autoantibody levels, such as in
Alzheimer’s disease, where decreased levels of Aβ-ab are
detected, or in Parkinson’s disease, where decreased
levels of the antibody against α-synuclein, a protein in-
volved in the pathogenesis of the disease, was found
[65]. Studies propose, that decreased levels of the natural
autoantibody Aβ-ab in Alzheimer patients lead to a loss
of protective effects of the ab and therefore to the de-
position of Aβ in the brain [66]. In recent research on a
Fig. 7 (See legend on next page.)
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Fig. 7 Changed mitochondrial apoptosis pathway in RGC-5 conditioned of treatment with 14-3-3 sigma antibodies. a: This graph shows several
of the significantly differently regulated proteins in the cells incubated with 14-3-3 antibodies in comparison to control cells. The proteins listed
here in some way all are involved in the mitochondrial apoptosis pathway. The changes of the proteins are shown in percent. b: This graph
schematically visualizes the significantly changed proteins of the mitochondrial apoptosis pathway. Proteins highlighted in green were found to
be significantly down-regulated) and proteins highlighted in red significantly up-regulated. The protein 14-3-3 interacts with p53, which is also
shown in the graph. It is conceivable that the modulation of 14-3-3 through 14-3-3 sigma antibodies leads to a changed interaction of p53 and
thereby to changed expression of p53 target genes such as PRAF2, S100A4 and BAX, which are significantly changed in the cells incubated with
14-3-3 abs. BAX plays a role in releasing cytochrome c from the mitochondrion. Cytochrome C interacts with caspase3, which triggers apoptosis
of the cells. It also is conceivable that the interaction of 14-3-3 and STAT3 is altered, which comes to the up-regulation of BIRC6. Another protein
which plays also a role in mitochondrial apoptosis is the anti-apoptotic ERK1, which is up-regulated in 14-3-3 sigma treated RGC-5 as well the
down-regulation of VDAC 1/2/3
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performed with intravenous Immunoglobulin’s (Ig) show-
ing a reduction of plasma concentration of Aβ1–42 [67].
These results underline our hypothesis, that changes
found in the natural autoimmunity of patients suffering
from neurodegenerative diseases such as Alzheimer’s or
glaucoma have an impact on the pathogenesis of the dis-
ease, showing that also the down-regulated autoanti-
bodies have an impact on the regulatory functions and
therefore their reduction is most possibly causing vul-
nerability to damage. We are aware of the fact that
RGC-5 cells are not a pure retinal ganglion cell line.
Nevertheless, a recently published article summarised
the characteristics of RGC-5 and their usage as a cell
model line. The authors stated that the majority of the
published articles characterising RGC-5 cells showed
Brn3, as well as Thy 1 staining, whereas only two papers
were not able to detect these markers. Furthermore nes-
tin expression was detected in RGC-5 cells, leading to
the conclusion that these cells are of neuronal origin.
The authors conclude that RGC-5 cells can act as retinal
cell line of neuronal origin in order to follow up initial
hypothesis [27].
Conclusion
In conclusion we were able to show changes in the pro-
tein profiles of the cells incubated with POAG serum,
especially of proteins involved in regulatory cell mecha-
nisms. In a further step we were able to demonstrate
that 14-3-3 abs, which are down-regulated in glaucoma
patients have protective effects on RGC-5 cells and are
transported into the cells. We were able to detect several
proteins changed in an anti-apoptotic manner in those
cells incubated with 14-3-3 abs. Altogether these results
underline our hypothesis that the changes in the natural
autoimmunity found in the serum of patients with the
neurodegenerative disease glaucoma play a role in the
disease pathogenesis. These results can be seen in ac-
cordance with results derived from studies performed
for Alzheimer’s disease. We believe that by losing regula-
tory effects of down-regulated autoantibodies, retinal
ganglion cells could become more vulnerable to otherstress factors and apoptosis of the cells could be pro-
voked e.g. by an elevated IOP.
Additional files
Additional file 1: Figure S1. This graph shows the autoantibody levels
of the 14-3-3 antibody in the serum of glaucoma patients in comparison to
healthy subjects (n = 45). Microarray meassurements of the sera were
performed. Glas slides coated with nitrocellulose were spotted with different
antigens, also including the 14-3-3 antigen. Then the slides were incubated
with the sera of either healthy people or patients suffering from primary
open angle glaucoma. The antibodies in the serum bind to their antigen.
The bound antibodies are then detected using a secondary antibody to IgG
(bound with Cy3). Using a Affymetrix Array scanner, the spots are scanned.
The intensity of the bound antibody is analyzed using the intensity of the
labelling of the secondary antibody and a comparison between healty and
glaucomatous serum is performed. A discrimance analysis was performed in
order to detect significant differences. Shown ist the mean of the Intensity
(U) with the standard error. We were able to detect a significantly lower
level of 14-3-3 antibody in the serum of POAG patients (p < 0.01).
Additional file 2: Figure S2. RGC-5 were preincubated with different
anti-myoglobin antibody concentrations and additionally stressed with
20 mM glutamate for 24 h, or 1.5 μM stauorsporine for 5 h. Cell viability was
determined using crystal violet and expressed as percent of the control
cells + the stress factor (glutamate or staurosporine) (* = p < 0.05; **p < 0.01).
This graph shows the results of the cells stressed with glutamate. No
protective effect of the antibody can be seen.
Additional file 3: Figure S3. Non-stressed RGC-5 cells were incubated
with the different 14-3-3 ab concentrations (0.05, 0.1, 0.5, 1, 5 and 10 μg/
ml). Viability was measured with crystal violet. We were not able to detect
any significant changes in the viability of the cells. The graph shows the
different cell groups on the X- axis and the viability in % on the Y- axis.
Additional file 4: Table S1 We were able to identify 1204 proteins in
the cells. 225 of the proteins were significantly differently regulated in
the cells incubated with 14-3-3 antibody in comparison to control cells
(>2 fold increased or <2 fold decreased). The significantly changed
proteins are listed in Additional file 4: Table S1.
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